Ganetespib also failed to meet its endpoints as a single agent in metastatic breast cancer, although signs of effectiveness were seen in certain sub-groups.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.